Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441876 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07441876 is a Phase 2 study that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 160 participants.
The verdict
NCT07441876, a Phase 2 study, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.
Interventions
- DRUG Vosoritide Injection [Voxzogo]
- DRUG BMN 333
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441876
The ClinicalTrials.gov registry entry for NCT07441876 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vosoritide Injection [Voxzogo] is the first listed.
NCT07441876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07441876 about?
NCT07441876 is a clinical study titled "Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia". This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.
What is the current status of trial NCT07441876?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-04-20. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07441876?
The interventions under investigation include: Vosoritide Injection [Voxzogo] (DRUG), BMN 333 (DRUG).
Who is sponsoring clinical trial NCT07441876?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.